Browsing Tag
MASH
9 posts
From metabolism to genetics: Can ARO-PNPLA3 change the MASH playbook
Can ARO-PNPLA3 reshape MASH drug development? Discover how Madrigal Pharmaceuticals, Inc. is expanding into precision therapies.
GSK to sell linerixibat rights to Alfasigma for up to $690m as rare liver disease drug nears FDA approval
GSK and Alfasigma agree worldwide licence for linerixibat, a rare liver disease itch drug nearing FDA approval. Deal worth up to $690 million. Read more.
Why MetaVia’s patent move may matter more than early weight loss data in the obesity market
MetaVia Inc. secures patent protection for its dual incretin obesity drug DA-1726 through 2041. Find out why this matters for investors and competitors.
MetaVia (NASDAQ: MTVA) raises $9.3m to advance DA-1726 after positive Phase 1b obesity data
MetaVia raised $9.3M to fund DA-1726 after strong obesity trial results. Find out how this dual-agonist strategy could reshape the GLP-1 landscape.
MetaVia unveils breakthrough Phase 2a data showing vanoglipel improves liver markers and glucose control in MASH patients
Find out how MetaVia’s vanoglipel improved liver enzymes and glucose control in its Phase 2a MASH trial — see why investors are taking notice today.
Can Sagimet turn denifanstat into a multi-indication platform and licensing engine beyond acne?
Can Sagimet parlay its acne win into a licensing engine and platform biotech story? Explore how FASN inhibition is being redefined across diseases.
From GLP-1 to FGF21: How Novo Nordisk’s Akero Therapeutics deal signals a new era in metabolic drug dominance
Novo Nordisk’s $5.2 B Akero deal adds the FGF21 drug efruxifermin to its MASH portfolio. See how it expands the company’s metabolic dominance.
Sen-Jam’s SJP-002C gets FDA-ready CMC milestone as investors eye late-stage trial momentum
Sen-Jam finalizes NDA-ready CMC deliverables for SJP-002C with KVK Tech and expands investor engagement, positioning for Phase 2b/3 trials.
MetaVia unveils synergistic liver disease data on DA-1241 and Efruxifermin at ADA 2025
MetaVia unveils ADA 2025 pre-clinical data showing DA-1241 and Efruxifermin combo improves MASH liver inflammation and fibrosis beyond monotherapies.